Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Other financing activities (2017 - 2021)

Spero Therapeutics' Other financing activities history spans 5 years, with the latest figure at -$163000.0 for Q4 2021.

  • For Q4 2021, Other financing activities fell 143.7% year-over-year to -$163000.0; the TTM value through Dec 2022 reached -$63000.0, down 175.9%, while the annual FY2021 figure was $248000.0, 73.98% down from the prior year.
  • Other financing activities reached -$163000.0 in Q4 2021 per SPRO's latest filing, down from $100000.0 in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $3.1 million in Q4 2017 to a low of -$753000.0 in Q2 2018.
  • Average Other financing activities over 5 years is $293294.1, with a median of $109000.0 recorded in 2021.
  • Peak YoY movement for Other financing activities: plummeted 1830.77% in 2018, then skyrocketed 2100.0% in 2020.
  • A 5-year view of Other financing activities shows it stood at $3.1 million in 2017, then tumbled by 75.58% to $749000.0 in 2018, then crashed by 89.45% to $79000.0 in 2019, then soared by 372.15% to $373000.0 in 2020, then plummeted by 143.7% to -$163000.0 in 2021.
  • Per Business Quant, the three most recent readings for SPRO's Other financing activities are -$163000.0 (Q4 2021), $100000.0 (Q3 2021), and $109000.0 (Q2 2021).